Current treatment status-Not currently treated Posts on Medivizor
Navigation Menu

Current treatment status-Not currently treated Posts on Medivizor

Optimal treatment for relapsed and unresponsive nodular lymphocyte-predominant Hodgkin lymphoma

Posted by on Apr 18, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate treatments and outcomes for patients with relapsed or unresponsive nodular lymphocyte-predominant Hodgkin lymphoma. This study concluded that these patients have a good overall prognosis and treatments should be chosen individually. Some background Radiotherapy (RT), chemotherapy (CT) and rituximab...

Read More

New treatment improves tumor response in patients with HER2 positive metastatic colorectal cancer

Posted by on Apr 8, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of pertuzumab (Perjeta) and trastuzumab (Herceptin) in patients with colorectal cancer and HER2 mutation (an abnormal gene). Researchers suggested that this treatment could be a safe option for patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC). Some background...

Read More

Comparing conditioning regimens before stem cell transplantation for patients with Hodgkin lymphoma

Posted by on Mar 28, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of two chemotherapy regimens before autologous stem cell transplantation (ASCT) for patients with Hodgkin lymphoma (HL). This study concluded that BEAM conditioning before ASCT significantly improved the outcomes of these patients. Some background About 20 – 30% of patients...

Read More

The impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned stem cell transplant

Posted by on Mar 26, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT). This study concluded that the graft-versus-lymphoma effect leads...

Read More

The impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned stem cell transplant

Posted by on Mar 26, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT).  This study concluded that the graft-versus-lymphoma effect leads to...

Read More

Allogenic hematopoietic stem cell transplant for patients with unresponsive acute myeloid leukemia

Posted by on Mar 20, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of allogeneic hemopoietic stem cell transplant (alloHSCT) in patients with unresponsive acute myeloid leukemia. This study concluded that alloHSCT is the best treatment option for these patients. Some background Patients with unresponsive acute myeloid leukemia (AML) are those...

Read More

Evaluating ibrutinib plus nivolumab for relapsed or refractory non-Hodgkin’s lymphoma

Posted by on Feb 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of ibrutinib (Imbruvica) plus nivolumab (Opdivo) for relapsed or unresponsive non-Hodgkin’s lymphoma (NHL). This study concluded that this treatment was well-tolerated and showed promising effectiveness in these patients. Some background Treatment remains challenging for high-risk...

Read More

Is BRESHAP an effective treatment for relapsed and unresponsive Hodgkin lymphoma?

Posted by on Feb 8, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined how safe and effective brentuximab vedotin (Adcedris) is when added to conventional treatments for relapsed and unresponsive Hodgkin lymphoma.  This study concluded that this treatment is safe and effective when used as part of the treatment for Hodgkin lymphoma. Some background Standard treatment for...

Read More

Comparing ibrutinib and ofatumumab in patients with previously treated chronic lymphocytic leukemia

Posted by on Jan 28, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate patient well-being and patient-reported outcomes in previously treated patients with chronic lymphocytic leukemia who receive ibrutinib (Imbruvica) or ofatumumab (Arzerra). They concluded that ibrutinib can improve quality of life while prolonging survival in these patients. Some background...

Read More

Evaluating BEAM conditioning for allogeneic stem cell transplantation in patients with relapsed or unresponsive lymphoma

Posted by on Jan 17, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of BEAM (carmustine, etoposide, cytarabine, and melphalan) chemotherapy before allogeneic hematopoietic cell transplantation (alloHCT; transferring healthy cells from a donor) for relapsed or unresponsive lymphoma. This study concluded that alloHCT with BEAM chemotherapy is an alternative...

Read More